Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL

NCT05390749 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Primary Central Nervous System Lymphoma

Interventions

DRUG: Orelabrutinib
DRUG: Pomalidomide
DRUG: Rituximab
DRUG: Methotrexate

Sponsor

Peking Union Medical College Hospital

Collaborators

[object Object]
[object Object]